StockWatch
·
LIOTECH INDUSTRIES LTD · QQ2 FY-2027 · THE CALL

Capex bet on 2.5x capacity; execution risk on margin targets

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsLIOTECHLiotech Industries Ltd17 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade B

First earnings call post-June 2026 IPO; no prior guidance to compare. H1 delivered strong margins (18.46% EBITDA) but management cites 14% and targets only 15%-16% forward — downside surprise implicit in guidance level.

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Strong demand and pricing power evidenced by 88% utilization and INR6+ Cr advance orders post-IPO. But margin guidance (15%-16% EBITDA forward) contradicts H1 actual of 18.46%, signaling either operational headwinds ahead or conservative guidance. Capex execution over next 2-3 months is make-or-break for delivery on 2.5x capacity promise; no track record yet.

₹33.64 Cr

Revenue · +null% YoY

₹3.54 Cr

Reported PAT · +null% YoY

Flat

Margins · vs guidance: Unverified

Did the claims hold up?

Management's claims vs. the numbers

118% CAGR revenue growth in recent period

OVERSTATED

H1 FY27 revenue INR33.64 Cr; prior capacity 4MT/day in FY25, now 8MT/day; revenue growth claims unsubstantiated by specific YoY numbers

Advance orders worth INR6+ crores with 30-day execution timeline

MET

June 2026 domestic purchase order INR6.46 crores mentioned; confirms order book depth and customer traction

EBITDA margin 15%-16% target post-capex

MISS

H1 FY27 actual 18.46% (INR6.21 Cr on INR33.64 Cr revenue); management cites current 14% and targets 14%-15% going forward — lower than reported

88% capacity utilization, nearly at max

MET

Confirmed in Q&A; supports demand narrative but tight constraint for near-term growth without capex

Earnings quality

What changed since the last call

Deltas vs. the prior call

Post-IPO product pricing +5%

Upgrade

Selling price increased INR100→INR105 per product after June 2026 listing; management cites improved inquiries and pricing power post-public offering.

Capacity constraint emergence

Downgrade

88% utilization forces capex bet; prior ad-hoc 12-hour shift to 8MT/day now insufficient. Expansion necessary to unlock geographic/export growth.

Margin guidance downside vs. H1 actual

Downgrade

H1 FY27 EBITDA 18.46%; forward guidance 14%-15%, suggesting 300-400 bps headwind from capex depreciation, working capital, or operational drag.

Defense tender market entry

New

INR60 lakh license investment for defense procurement; tendered pre-IPO; revenue upcall uncertain and not quantified.

The Q&A

Moderate Q&A pressure on margins (Mukesh Panjwani, Vishvender Singh). Management held margins at 14%-15% target despite questions on capex depreciation and working capital. Some evasion on employee cost drop (attributed to 6-month vs. full-year timing). Direct and candid on capacity constraints and capex timeline.

The exchanges that mattered

Capacity & capex timeline — Mukesh Panjwani, WC Securities

Answered

88% utilization (almost max); construction to complete in 1-2 months; capex utilization in next 2-3 months. Post-expansion capacity >5,000 metric tons/annum, more than double current.

Margin trajectory post-capex — Mukesh Panjwani, WC Securities

Partial

EBITDA margin target 14%-15% (vs. 18.46% H1 actual); will increase after capex with high-margin products and marketing investment. No specific post-capex EBITDA bridge provided.

Capacity data granularity — Vishvender Singh, Prudent Equity

Answered

FY25 start: 4 MT/day; now 8 MT/day (12-hour shift); post-expansion >2.5x, >5000 MT/annum or 16+ MT/day (24-hour capable).

EBITDA margin sustainability — Vishvender Singh, Prudent Equity

Dodged

Current EBITDA 14% (after loan repayment benefits); targeting 14%-15% forward. Last 3 years maintained ~15%. June IPO reduced interest burden.

Customer segments & SKU diversification — Milind Shah, individual investor

Answered

150+ SKUs; B2B model (dealers, distributors, stockists); main revenue from 9 states; demand from residential, commercial sectors; advance order >INR6 Cr.

Defense tender qualification — Vishvender Singh, Prudent Equity

Dodged

Defense tender license; scientist visit required for qualification; if qualified, 100% fund refunded; product line related to engineering services.

IPO fund utilization status — Abhishek Malhotra, Family Office

Answered

INR10 Cr for capex/machinery; almost complete; machinery purchase modernization ongoing, will complete in 2 months.

Capex rationale vs. 24-hour shift option — Shiv Motto, Liotech Industries

Answered

Only 8 labor quarters (8 families); capex adds 12 quarters → 20 families. Modernization required for machinery procurement and local facility approvals. All interconnected.

Margin impact on geographic expansion — Shiv Motto, Liotech Industries

Partial

No margin impact if pricing set per margin setup; product price list standardized per margin. Post-expansion, plan for high-margin products to offset.

Receivable days and working capital — Shiv Motto, Liotech Industries

Answered

43-44 days (vs. 45-day MSME benchmark); some payment delay post-Sep; planning per 45-day MSME norm. Recovered INR20 lakh interest on receivables.

Employee cost halving in H1 — Vishvender Singh, Prudent Equity

Answered

No employee reduction; 6-month H1 salary (INR81 lakh) vs. full-year salary in prior year (INR1.2 Cr). No staff reduction.

Selling price increase post-IPO — Vishvender Singh, Prudent Equity

Answered

INR100→INR105 per product (5% increase). Increased inquiries post-listing, improvement in existing customers year-wise.

Export expansion plans — Leo Fernandez, individual investor

Partial

Planning South Africa, Gulf, other European countries. Opportunity ongoing; no specific revenue or timeline quantified.

Guidance

Forward guidance and management's confidence

No specific FY27/FY28 revenue target provided

Low

Management alludes to 118% CAGR historically but no forward revenue guide. Only capacity & margin targets given.

EBITDA margin 15%-16% post-capex (target, vs. 14% current)

Medium

H1 actual 18.46% contradicts current 14% cite; suggests post-IPO loan repayment boost offset by expansion drag. Post-capex high-margin SKU launch expected to lift margin.

Net margin 10%-11% (target, vs. 10.51% H1 actual)

Medium

Sustainable at current run-rate; capex depreciation may weigh near-term but management targets offset via product mix.

Capex completion within 1-2 months; utilization within 2-3 months thereafter

Medium

INR10 Cr capex (machinery, facility modernization); construction to finish by Dec 2026/Jan 2027. Benefits flagged for FY28.

Post-capex capacity >5000 MT/annum (>2.5x current, >200% increase)

Medium

Current 8 MT/day (12-hour shift) → 16+ MT/day (24-hour capable) post-expansion. Facility footprint expansion to ~12,632 sq ft.

Risks the call surfaced

Ranked by how much they should concern a holder

Capex execution & stranded capacity

High

Capex bet on >2.5x capacity; if demand stalls post-expansion, ROI erodes and capex depreciation crushes margin. No binding forward orders beyond INR6 Cr.

Margin compression from capex depreciation

Medium

H1 EBITDA 18.46%; forward target 14%-15%. 300+ bps downside embedded. If capex depreciation and working capital drain exceed high-margin product offset, target miss likely.

Geographic concentration & expansion execution

Medium

Operating in 9 states out of 36; 75% of addressable market untapped. Expansion execution (new distributors, regulatory compliance, working capital) may dilute margins and slow revenue growth.

Customer concentration & B2B channel risk

Medium

100% B2B model (dealers, distributors, stockists); no large OEM contracts disclosed. Single large customer loss could materially impact revenue.

Raw material (steel) price volatility

Medium

Steel prices remained firm in H1 FY27. 5% price fluctuation pass-through threshold; above 5%, customer bears cost; below 5%, company bears. 95+ bps margin at risk.

Defense tender qualification contingency

Low

INR60 lakh license investment for defense tender; scientist visit required for qualification. If fail, 100% refund claimed but refund timing opaque.

Management

Score 7/10. Candid on capacity constraints, capex rationale, and margin compression. Some evasion on employee cost drop (attributed to 6-month vs. full-year timing) and defense tender specifics. Provides specific numbers on capacity, pricing, margins. First earnings call post-IPO; track record short. IPO deployment executed (INR24.25 Cr deployed for machinery, loan repayment, working capital). Capex timeline clear (1-2 months). No misses yet but no large-scale execution history.

What to watch next
  • 1 · Dec 2026 (est.)

    Capex modernization completion; new machinery commissioning

  • 2 · Jan-Mar 2027

    Post-capex utilization; 2.5x capacity ramp and high-margin SKU launch

  • 3 · FY28

    Margin expansion to 15%-16% EBITDA (management target); export revenue from South Africa, Gulf

Capex execution over next 2-3 months is make-or-break for delivery on 2.5x capacity promise; no track record yet.

Informational and educational content only. Not investment advice.

Capex bet on 2.5x capacity; execution risk on margin targets — StockWatch